The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact
Open accessAbstract
In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized by an acute deterioration in respiratory symptoms, are fundamental events impacting negatively upon disease progression, comorbidities, wellbeing and mortality. ECOPD also represent the largest component of the socioeconomic burden of COPD. ECOPDs are currently defined as acute worsening of respiratory symptoms that require additional therapy. Definitions that require worsening of dyspnoea and sputum volume/purulence assume that acute infections, especially respiratory viral infections, and/or exposure to pollutants are the main cause of ECOPD. But other factors may contribute to ECOPD, such as the exacerbation of other respiratory diseases and non‐respiratory diseases (e.g., heart failure, thromboembolism). The complexity of worsening dyspnoea has suggested a need to improve the definition of ECOPD using objective measurements such as blood counts and C‐reactive protein to improve accuracy of diagnosis and a personalized approach to management. There are three time points when we can intervene to improve outcomes: acutely, to attenuate the length and severity of an established exacerbation; in the aftermath, to prevent early recurrence and readmission, which are common, and in the long‐term, establishing preventative measures that reduce the risk of future events. Acute management includes interventions such as corticosteroids or antibiotics and measures to support the respiratory system, including non‐invasive ventilation (NIV). Current therapies are broad and better understanding of clinical phenotypes and biomarkers may help to establish a more tailored approach, for example in relation to antibiotic prescription. Other unmet needs include effective treatment for viruses, which commonly cause exacerbations. Preventing early recurrence and readmission to hospital is important and the benefits of interventions such as antibiotics or anti‐inflammatories in this period are not established. Domiciliary NIV in those patients who are persistently hypercapnic following discharge and pulmonary rehabilitation can have a positive impact. For long‐term prevention, inhaled therapy is key. Dual bronchodilators reduce exacerbation frequency but in patients with continuing exacerbations, triple therapy should be considered, especially if blood eosinophils are elevated. Other options include phosphodiesterase inhibitors and macrolide antibiotics. ECOPD are a key component of the assessment of COPD severity and future outcomes (quality of life, hospitalisations, health care resource utilization, mortality) and are a central component in pharmacological management decisions. Targeted therapies directed towards specific pathways of inflammation are being explored in exacerbation prevention, and this is a promising avenue for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–207 of 207
Human rhinovirus infection and COPD: role in exacerbations and potential for therapeutic targets
Cafferkey, J., Coultas, J. A., & Mallia, P. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1764354 · Cited by 27
Chen, K., Pleasants, K. A., Pleasants, R. A., Beiko, T., Washburn, R. G., Yu, Z., Zhai, S., & Drummond, M. (2020) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2020.1766433 · Cited by 26
Zhang, J., Chang, C. H., Ning, S., Zhu, H., Bei, H., & Yao, W.-Z. (2015) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2015.01.011 · Cited by 24
Zhang, J., Chang, C. H., Ning, S., Zhu, H., Bei, H., & Yao, W.-Z. (2015) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2015.05.029 · Cited by 23
Shafuddin, E., Chang, C. L., Cooray, M., Tuffery, C. M., Hopping, S., Sullivan, G., Jacobson, G. A., & Hancox, R. J. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.11.008 · Cited by 20
Dissecting COPD exacerbations: time to rethink our definition
Celli, B. R. (2017) · European Respiratory Journal · doi:10.1183/13993003.01432-2017 · Cited by 19
Self-citationHead-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
Threapleton, C. J., Janjua, S., Normansell, R., & Baker, E. H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013024.pub2 · Cited by 16
Metadata
- Authors
- MacLeod, M., Papi, A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J. A., & Fabbri, L. M.
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2021-04-24
- Volume
- 26
- Issue
- 6
- Pages
- 532-551
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- OpenAlex
- W3156431662
- Cited by
- 359
- References
- 207
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.